Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company
developing tumor-selective immuno-oncology therapies for people
living with cancer, today announced the appointment of Tomas J.
Heyman to the company’s board of directors. Mr. Heyman is a
biopharmaceutical veteran with nearly 40 years of leadership and
management expertise in corporate strategy, business development
and venture capital from his tenure with Johnson & Johnson
(J&J). In addition, the company announced that John Maraganore,
Ph.D., former founding CEO of Alnylam Pharmaceuticals, will serve
as a strategic advisor to Xilio’s board of directors and its
executive team.
“Tom brings extensive global leadership experience
from his tenure at J&J and has a strong track record of driving
value creation and business development. John is an industry
pioneer who built Alnylam from an early research platform concept
to a global therapeutics company with multiple novel medicines. The
collective experience of Tom and John will be highly valuable as
Xilio continues to advance its innovative scientific platform and
promising pipeline of tumor-selective immunotherapy programs,” said
Paul Clancy, chair of the board of directors of Xilio Therapeutics.
“We are thrilled to welcome Tom to the Xilio board of directors and
John as a strategic advisor to the company, and we look forward to
working with each of them and benefiting from their extensive
strategic knowledge and expertise.”
“Xilio is pioneering an innovative platform to
develop tumor-selective immunotherapies that have the potential to
achieve meaningful anti-tumor activity while minimizing serious,
systemic effects,” said Mr. Heyman. “I look forward to partnering
with Xilio’s high-caliber board and leadership team as it seeks to
advance its pipeline of potentially transformative clinical and
pre-clinical programs.”
“I have known Rene and the Xilio team for some
time, and I have been impressed with their approach, which is
intended to precisely deliver immunotherapies directly to the tumor
microenvironment minimizing their systemic side effects and
improving their potency,” said Dr. Maraganore. “I am excited to
partner with the team as a strategic advisor to advance their novel
platform and work to bring the next generation of immune-oncology
therapies to patients.”
In addition, Xilio announced the appointment of
Myles Clouston to the newly created position of vice president of
investor relations, where he will lead the company’s investor
relations strategy and engagement. Mr. Clouston brings more than 20
years of experience to this role, with a strong understanding of
the life science sector from his time at MorphoSys and Mylan (now
Viatris) and nearly a decade of global investor relations,
corporate development, and capital markets experience from his
roles at NASDAQ, J&J, and Thomson Financial Corporate
Services.
Tomas J. HeymanMr. Tomas Heyman
brings significant biopharmaceutical experience in corporate
strategy, business development, venture capital, as well as
R&D, legal and operational management experience. Mr. Heyman
most recently served as president of JJDC, J&J’s corporate
venture capital group, until September 2019, where he managed
approximately $1.5 billion in capital and oversaw investments in
more than 120 companies. Prior to leading JJDC, he led business
development for J&J’s pharmaceutical group, Janssen, for over
20 years, completing hundreds of licensing and M&A
transactions. He was also the managing director of Janssen
Pharmaceutica, Belgium, J&J’s largest subsidiary outside the
U.S., and vice president of licensing at Ortho Pharmaceutical, a
J&J affiliate. Mr. Heyman currently serves as a member of the
boards of directors of Legend Biotech, Akero Therapeutics,
OptiNose, and Adagio Therapeutics. Mr. Heyman received his
Master of Law from K.U. Leuven in Belgium and completed
post-graduate studies in international law in Geneva, Switzerland,
and post-graduate studies in business management at the University
of Antwerp in Belgium.
John M. Maraganore, Ph.D.Dr. John
Maraganore served as the founding chief executive officer and a
director of Alnylam Pharmaceuticals from 2002 to 2021 and is a
member of the Alnylam Scientific Advisory Board. During his tenure,
he built and led the company from early platform research on RNA
interference through global approval and commercialization of the
first four RNAi therapeutics medicines, ONPATTRO®, GIVLAARI®,
OXLUMO®, and Leqvio®. He also led Alnylam’s value creation
strategy, building $25B in market capitalization and forming over
20 major pharmaceutical alliances. Previously, Dr. Maraganore held
leadership and scientific roles at Millennium Pharmaceuticals,
Biogen, Zymogenetics, and The Upjohn Company. He is currently a
venture partner at ARCH Venture Partners, a venture advisor at
Atlas Ventures, an executive partner at RTW Investments, and senior
advisor for Blackstone Life Sciences. He is chair of the board of
directors of Hemab Therapeutics and the chairman and co-founder of
Orbital Therapeutics. Dr. Maraganore also serves as a member of the
board of directors of Agios Pharmaceuticals, Beam Therapeutics,
Kymera Therapeutics, ProKidney, and the Biotechnology Industry
Organization, where he was chair from 2017-2019 and serves as chair
emeritus. In addition, he serves on the board of the Termeer
Foundation, chair of the n-Lorem Foundation Advisory Council, and
on the advisory board of Ariadne Labs. Dr. Maraganore received his
M.S. and Ph.D. in biochemistry and molecular biology at the
University of Chicago.
About Xilio TherapeuticsXilio
Therapeutics is a clinical-stage biotechnology company focused on
harnessing the immune system to achieve deep and durable clinical
responses to improve the lives of patients with cancer. The company
is using its proprietary geographically precise solutions (GPS)
platform to rapidly engineer novel molecules, including cytokines
and other biologics, that are designed to optimize their
therapeutic index. These molecules are designed to localize
activity within the tumor microenvironment without systemic
effects, resulting in the potential to achieve enhanced anti-tumor
activity. Xilio is building a pipeline of wholly owned,
tumor-selective, GPS-enabled cytokine and checkpoint inhibitor
product candidates, including its clinical-stage programs, XTX101,
a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a
tumor-selective IL-2, as well as its earlier pipeline, including
XTX301, a tumor-selective IL-12. For more information, please
visit www.xiliotx.com and follow us on Twitter (@xiliotx)
and LinkedIn (Xilio Therapeutics, Inc.).
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
statements regarding plans, strategies, timelines and expectations
for Xilio’s current or future product candidates; the potential
benefits of any of Xilio’s current or future product candidates in
treating patients; and Xilio’s strategy, goals and anticipated
financial performance, milestones, business plans and focus. The
words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “seek,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of important risks, uncertainties and
other factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to ongoing and planned
research and development activities, including initiating,
conducting or completing preclinical studies and clinical trials
and the timing and results of such preclinical studies or clinical
trials; the delay of any current or planned preclinical studies or
clinical trials or the development of Xilio’s current or future
product candidates; Xilio’s ability to obtain and maintain
sufficient preclinical and clinical supply of current or future
product candidates; Xilio’s advancement of multiple early-stage
programs; Xilio’s ability to successfully demonstrate the safety
and efficacy of its product candidates and gain approval of its
product candidates on a timely basis, if at all; results from
preclinical studies or clinical trials for Xilio’s product
candidates, which may not support further development of such
product candidates; actions of regulatory agencies, which may
affect the initiation, timing and progress of current or future
clinical trials; Xilio’s ability to obtain, maintain and enforce
patent and other intellectual property protection for current or
future product candidates; Xilio’s ability to obtain and maintain
sufficient cash resources to fund current or future operating
expenses and capital expenditure requirements; the impact of
international trade policies on Xilio’s business, including U.S.
and China trade policies; and the impact of the COVID-19 pandemic
on Xilio’s business, operations, strategy, goals and anticipated
milestones. These and other risks and uncertainties are described
in greater detail in the sections entitled “Risk Factor Summary”
and “Risk Factors” in Xilio’s filings with the U.S. Securities and
Exchange Commission (SEC), including Xilio’s most recent Quarterly
Report on Form 10-Q and any other filings that Xilio has made or
may make with the SEC in the future. Any forward-looking statements
contained in this press release represent Xilio’s views only as of
the date hereof and should not be relied upon as representing its
views as of any subsequent date. Except as required by law, Xilio
explicitly disclaims any obligation to update any forward-looking
statements.
This press release contains hyperlinks to
information that is not deemed to be incorporated by reference in
this press release.
For Investor Inquiries:Myles
Clouston Vice President, Investor
Relationsinvestors@xiliotx.com
For Media Inquiries: Julissa
VianaVice President, Corporate Communicationsmedia@xiliotx.com
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Apr 2023 to Apr 2024